U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT07600476) titled 'A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors' on April 30.
Brief Summary: The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Cutaneous Melanoma
Mucosal Melanoma
Cutaneous Squamous Cell Carcinoma (CSCC)
Merkel C...